| Literature DB >> 24910558 |
Abstract
High-mobility group box 1 (HMGB1) protein first made headlines 40 years ago as a non-histone nuclear protein that regulates gene expression. Not so long ago, it was also shown that HMGB1 has an additional surprising function. When released into the extracellular milieu, HMGB1 triggers an inflammatory response by serving as an endogenous danger signal. The pro-inflammatory role of HMGB1 is now well-established and has been associated with several diseases, including sepsis, rheumatoid arthritis, and atherosclerosis. Yet very little is known about its role in obesity, wherein adipose tissue is typified by a persistent, smoldering inflammatory response instigated by high macrophage infiltrate that potentiates the risk of obesity-associated comorbidities. This mini-review focuses on the putative causal relationship between HMGB1 and macrophage pro-inflammatory activation in pathologically altered adipose tissue associated with obesity.Entities:
Keywords: adipocyte; adipose tissue; apoptosis; cell death; crown-like structure; damage-associated molecular patterns; danger signals; diabetes mellitus type 2; free fatty acids; high-mobility group box 1 protein; inflammation; insulin resistance; interleukin-6; lipid droplets; lipolysis; macrophage; necrosis; obesity; pattern-recognition receptors; phagocytosis; tumor-necrosis factor-α
Mesh:
Substances:
Year: 2014 PMID: 24910558 PMCID: PMC4031786
Source DB: PubMed Journal: Yale J Biol Med ISSN: 0044-0086
Figure 1Inflammatory responses to weight gain and weight loss. Early weight loss leads to an increase in the local release of lipids and to the recruitment of anti-inflammatory macrophages that regulate adipose tissue lipolysis. In contrast, weight gain results in the recruitment of pro-inflammatory macrophages. Necrotic adipocytes lose membrane integrity and release their intracellular contents, including HMGB1, and may stimulate macrophages to trigger an inflammatory response, which further contributes to obesity-associated comorbidities (e.g., insulin resistance, diabetes mellitus type 2).